Crovalimab
Based on 1 Customer Validation
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.59%
- CAS No.: 1917321-26-6
- Masse moléculaire:145.28 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
Complement C5
In Vitro
Crovalimab (SKY59; RO7112689; 0-100 μg/mL) inhibits haemolysis in classical pathway and reactive lysis systems[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Crovalimab (20 mg/kg; iv; a single dose) stably suppressed complement activity in plasma for 8 weeks[1].
Crovalimab (5 mg/kg by iv at day 0 and 2 mg/kg by sc at day 7, 21, 35, 49, and 63) causes over 20% of serum hemolytic activity in the cRBC lysis assay to correlate with events such as dysphagia and dramatic increases in lactate dehydrogenase (LDH) and alanine aminotransferase (ALT) levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Complement C5 Protein, Human (HEK293, His, HY-P700862) can bind Crovalimab. The EC50 for this effect is 5.406 ng/mL. -
Flow cytometric analysis of 1X106 HepG2 cells with Crovalimab (HY-P99965, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/50 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1917321-26-6
-
Appearance Liquid
-
Masse moléculaire 145.28 kDa
-
Color Colorless to light yellow
-
SMILES
[Crovalimab]
-
Synonyms
SKY59; RO7112689; RG-6107
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Taku Fukuzawa, et al. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci Rep. 2017 Apr 24;7(1):1080. [Content Brief]
[2]. Wioleta M Zelek, et al. Characterizing a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis. Immunology. 2018 Nov;155(3):396-403. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)